<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543854</url>
  </required_header>
  <id_info>
    <org_study_id>CRLX030A2201</org_study_id>
    <secondary_id>2011-000833-35</secondary_id>
    <nct_id>NCT01543854</nct_id>
  </id_info>
  <brief_title>Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure</brief_title>
  <official_title>A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-controlled Study to Evaluate the Hemodynamic Responses to Intravenous RLX030 Infusion in Subjects With Acute Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the hemodynamic effect of RLX030 infusion in subjects with acute heart
      failure. In addition safety and effects on renal function and biomarkers will be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak change from baseline of PCWP (pulmonary capillary wedge pressure)</measure>
    <time_frame>baseline, after 8 and 20 hrs treatment</time_frame>
    <description>Measurements will be made using a Swan-Ganz indwelling catheter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak change from baseline of CI (cardiac index)</measure>
    <time_frame>baseline, after 8 and 20 hrs treatment</time_frame>
    <description>Measurements will be made using a Swan-Ganz indwelling catheter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change over time of PCWP (pulmonary capillary wedge pressure)</measure>
    <time_frame>During 20 hours of infusion and up to 4 hours after stop of infusion</time_frame>
    <description>Measurements will be made using a Swan-Ganz indwelling catheter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over time of systemic vascular resistance (SVR)</measure>
    <time_frame>During 20 hours of infusion and up to 4 hours after stop of infusion</time_frame>
    <description>Measurements will be made using a Swan-Ganz indwelling catheter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over time of pulmonary vascular resistance (PVR)</measure>
    <time_frame>During 20 hours of infusion and up to 4 hours after stop of infusion</time_frame>
    <description>Measurements will be made using a Swan-Ganz indwelling catheter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over time of pulmonary arterial pressure (PAP)</measure>
    <time_frame>During 20 hours of infusion and up to 4 hours after stop of infusion</time_frame>
    <description>Hemodynamic measurements were made using a Swan-Ganz catheter when patients were in a supine position</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over time of pulmonary and peripheral oxygen saturation</measure>
    <time_frame>During 20 hours of infusion and up to 4 hours after stop of infusion</time_frame>
    <description>Hemodynamic measurements were made using a Swan-Ganz catheter when patients were in a supine position</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of RLX030: area under the serum concentration-time curve from time zero to infinity (AUCinf)</measure>
    <time_frame>During 20 hours of infusion and 24 hours after stop of infusion</time_frame>
    <description>Blood will be collected from an in dwelling catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of RLX030: area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)</measure>
    <time_frame>During 20 hours of infusion and 24 hours after stop of infusion</time_frame>
    <description>Blood will be collected from an in dwelling catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of RLX030: serum concentration over 20 hours of infusion (C20h)</measure>
    <time_frame>During 20 hours of infusion and 24 hours after stop of infusion</time_frame>
    <description>Blood will be collected from an in dwelling catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of RLX030: terminal elimination half-life (T1/2)</measure>
    <time_frame>During 20 hours of infusion and 24 hours after stop of infusion</time_frame>
    <description>Blood will be collected from an in dwelling catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of RLX030: mean residence time (MRT)</measure>
    <time_frame>During 20 hours of infusion and 24 hours after stop of infusion</time_frame>
    <description>Blood will be collected from an in dwelling catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of RLX030: volume of distribution at steady state following intravenous administration</measure>
    <time_frame>During 20 hours of infusion and 24 hours after stop of infusion</time_frame>
    <description>Blood will be collected from an in dwelling catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over time on calculated creatinine clearance</measure>
    <time_frame>During 20 hours of infusion and 4 hours after stop of infusion</time_frame>
    <description>Urine samples will be collected for analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over time in Diuresis</measure>
    <time_frame>During 20 hours of infusion and 4 hours after stop of infusion</time_frame>
    <description>Urine samples will be collected for analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central aortic systolic pressure-time curve</measure>
    <time_frame>During 20 hours of infusion and 24 hours after stop of infusion</time_frame>
    <description>A cuff will be used for a brachial blood pressure measurement and a wrist sensor for arterial pulse waveforms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radial augmentation index-time curve</measure>
    <time_frame>During 20 hours of infusion and 24 hours after stop of infusion</time_frame>
    <description>A cuff will be used for a brachial blood pressure measurement and a wrist sensor for arterial pulse waveforms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events, serious adverse events and death</measure>
    <time_frame>During 20 hours of infusion and 24 hours after stop of infusion</time_frame>
    <description>Adverse events will be assessed by signs/symptoms, clinical laboratory and electrocardiographs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>RLX030</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RLX030 as intravenous infusion for 20 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo as intravenous infusion for 20 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RLX030</intervention_name>
    <description>Intravenous infusion of RLX030 over 20 hrs</description>
    <arm_group_label>RLX030</arm_group_label>
    <other_name>serelaxin*</other_name>
    <other_name>*International Nonproprietary Name</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion of placebo over 20 hours</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients hospitalized or requiring admission to hospital for management of acute heart
             failure within the previous 48 hours.

          -  Pulmonary wedge pressure above or equal to18 mmHg determined by right heart
             catheterization

        Exclusion Criteria:

          -  Systolic blood pressure below 115 mmHg

          -  Significant valvular diseases or arrythmias

          -  Acute coronary syndrome in previous 45 days

          -  Treatment with mechanical support (intra-aortic balloon pump, endotracheal intubation,
             mechanical ventilation, or any ventricular assist device)

          -  Impaired renal or hepatic function

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>87 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1180AAX</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B1846BMF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halle/'Saale</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-981</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>127644</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>S.-Petersburg</city>
        <zip>198205</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St-Petersburg</city>
        <zip>198013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>192242</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2012</study_first_posted>
  <last_update_submitted>August 4, 2014</last_update_submitted>
  <last_update_submitted_qc>August 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>RLX030</keyword>
  <keyword>Hemodynamics</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

